GlassScriptPhysician profile
Shilpa Shetty
NPI 1316194517
$2,431.94
in general payments reported to CMS, 2019-2025
24 companies · $995 in 2025
The $995 reported for 2025 was more than what 85% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $251 · 2020: $72.14 · 2021: $177 · 2022: $127 · 2023: $459 · 2024: $350 · 2025: $995.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,790 · Education: $13.89.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,790.20 |
| Education | $13.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $644.45 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $366.04 | 2021-2025 | Jardiance, Mounjaro, Zepbound |
| Insulet Corporation | $298.30 | 2019-2025 | Omnipod |
| Amgen INC. | $218.23 | 2019-2025 | Evenity, Prolia, Prolia |
| Abbott Laboratories | $180.01 | 2020-2025 | Freestyle Libre 3 |
| Ascendis Pharma Endocrinology INC | $119.83 | 2025 | Yorvipath |
| Sequel Med Tech, LLC | $64.97 | 2025 | Twiist |
| Recordati_rare_diseases_inc. | $53.58 | 2025 | Isturisa |
| Tandem Diabetes Care, INC. | $48.84 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Almatica Pharma LLC | $47.62 | 2025 | Teriparatide |
| Astrazeneca Pharmaceuticals LP | $43.02 | 2023 | Farxiga |
| Corcept Therapeutics | $42.43 | 2023-2025 | Korlym |
| Medtronic, INC. | $40.49 | 2024-2025 | Minimed 780g |
| Beta Bionics, INC. | $37.59 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Embecta Corp. | $37.25 | 2023 | Bd Nano 2nd Gen Pen Needle |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mannkind Corporation | $32.70 | 2025 | |
| Neurocrine Biosciences, INC. | $30.99 | 2025 | |
| Amneal Pharmaceuticals LLC | $28.34 | 2025 | Unithroid |
| Xeris Pharmaceuticals, INC. | $20.95 | 2024 | Recorlev |
| Bayer Healthcare Pharmaceuticals INC. | $18.72 | 2023 | |
| Dexcom, INC. | $16.55 | 2023 | Dexcom G6 Transmitter |
| Acella Pharmaceuticals, LLC | $14.76 | 2025 | NP Thyroid 60 |
| Abbvie INC. | $14.41 | 2025 | |
| Medtronic Minimed, INC. | $11.87 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shilpa Shetty listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.